Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.parkreldis.2020.08.033 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Public Health.
Alzheimers Dement
December 2024
King's College London, London, United Kingdom; College of Medicine and Health, University of Exeter, Exeter, United Kingdom.
Psychosis is a common and distressing disorder in people with Alzheimer disease, associated with a poor clinical prognosis, an increased risk of institutionalization and for which there are no approved treatments. New approaches to diagnosis and symptom assessment and treatment are beginning to move the field forward, including the emergence of psychosis at the pre-clinical or even pre-cognitive impairment stages of disease in some individuals. The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART) research criteria for psychosis in neurodegenerative disease, and the ISTAART criteria for mild behavioural impairment are examples of recent developments.
View Article and Find Full Text PDFBackground: Experiencing behavioural symptoms such as aggression, agitation and psychosis contribute significantly to reduced quality of life amongst people with dementia. These behavioral symptoms can be considered more detrimental to overall well-being than cognitive impairment. In the UK, risperidone is the sole approved atypical antipsychotic for treating these symptoms, despite its notable risk of serious side effects, including stroke.
View Article and Find Full Text PDFBackground: We present Phase 1 trial data using the Neuropsychiatric Inventory ("NPI") domains, NPI-delusions and NPI-hallucinations as symptoms of psychosis in participants with Alzheimer's ("AD") receiving IGC-AD1, a combination of low concentration delta 9-tetrahydrocannabinol ("THC") and melatonin. Cannabis use is considered an established risk factor for psychosis in young people. Psychosis is prevalent in AD patients, with around 50% experiencing it, generating safety concerns regarding the use of THC in these patients.
View Article and Find Full Text PDFBackground: Dementia often includes behavioral and psychological symptoms such as behavioral excitement, mood disorders and psychosis. Antipsychotic drugs are often prescribed alone or in conjunction with cognitive enhancers, however, these drugs can increase risk for adverse cardiovascular/cerebrovascular events (MACCE) and mortality. This study investigated whether those prescribed antipsychotics and/or cognitive enhancers experienced a MACCE more quickly and if medication dosage impacts survival time.
View Article and Find Full Text PDFThree-Month Polysubstance Use Patterns Among People Enrolled in Outpatient Treatment for Methamphetamine Use.
Subst Use Misuse
January 2025
National Centre for Youth Substance Use Research (NCYSUR), School of Psychology, The University of Queensland, Brisbane, Australia.
Background: Polysubstance use is common among people who use methamphetamine. This prospective study examined the three-month polysubstance use profiles among people enrolled in outpatient treatment for methamphetamine use and associated substance use, mental health, and treatment correlates.
Method: The present study used routinely collected client-reported outcome measures data from = 1,507 clients enrolled in outpatient treatment who reported methamphetamine as their primary drug of concern ( = 34.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!